Drug - Rapaflo (silodosin)
Therapeutic area - benign prostatic hyperplasia (BPH)
FDA approved indication
Rapaflo, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Available as capsules: 8 mg and 4 mg
Patient has been tried on each of the following without success:
- doxazosin mesylate (Cardura)
- tamsulosin (Flomax)
- terazosin (Hytrin)
Rapaflo is available only as a branded medication and is associated with a list price of about $4.18/tablet. Conversely, other alpha blockers, doxazosin mesylate, tamsulosin hcl, terazosin hcl are all available as generic formulations and are available from $0.10 to $0.50, and are expected to offer the same efficacy profile.
MHCP Provider Call Center 651-431-2700 or 800-366-5411